Press release
(2021-2030) Biosimilar Hormones Market Data Analysis, Major Key Players : Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma.
Biosimilar Hormones Market
The biosimilar hormones market report describes and explains the global biosimilar hormones market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
Place A Direct Purchase Order Of The Report Here
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3432
The biosimilar hormones market consists of sales of biosimilar hormones by entities that engage in manufacturing biosimilar hormones. These hormones are used when patients have a drop in hormones in their bodies or are unbalanced. Only goods and services traded between entities or sold to end consumers are included.
The global biosimilar hormones market is expected to grow from $1.94 billion in 2020 to $2.19 billion in 2021 at a compound annual growth rate (CAGR) of 12.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar hormones market is expected to reach $5.35 billion in 2025 at a CAGR of 25%.
Request For The Sample Of The Biosimilar Hormones Market Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp
Some of the major players of the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma.
The countries covered in the global biosimilar hormones market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.
The regions covered in the global biosimilar hormones market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The global biosimilar hormones market is segmented -
1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Others
2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Others
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics
Read More On The Global Biosimilar Hormones Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-hormones-global-market-report-2020-30-covid-19-growth-and-change
Few Points From Table Of Content
1. Executive Summary
2. Biosimilar Hormones Market Characteristics
3. Biosimilar Hormones Market Trends And Strategies
4. Impact Of COVID-19 On Biosimilar Hormones
5. Biosimilar Hormones Market Size And Growth
.....
28. Biosimilar Hormones Pipeline Analysis
29. Key Mergers And Acquisitions In The Biosimilar Hormones Market
30. Biosimilar Hormones Market Future Outlook and Potential Analysis
31. Appendix
Contact Us
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
Interested to know more about The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model (www.globalmarketmodel.com) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release (2021-2030) Biosimilar Hormones Market Data Analysis, Major Key Players : Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma. here
News-ID: 2330020 • Views: …
More Releases from The Business research company
Blood Meal Market Surges: Reaches $2.06 Billion in 2024, Set to Grow to $2.37 Bi …
The blood meal market size has grown steadily in recent years. It will grow from $1.98 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to animal feed industry growth, meat and poultry production expansion, effective nutrient source, waste utilization in abattoirs, organic fertilizer production.
The blood meal market size is expected to see…
Beef Fat Market Growth Surges: Reaches $45.35 Billion in 2024, Set to Reach $61. …
The beef fat market size has grown strongly in recent years. It will grow from $42.17 billion in 2023 to $45.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increased livestock production trends, regulatory environment, health and nutritional trends, economic factors.
The beef fat market size is expected to see strong growth in the next few years.…
Antiviral Combination Therapy Market Surges: Reaches $54.5 Billion in 2024, Set …
The antiviral combination therapy market size has grown strongly in recent years. It will grow from $51.15 billion in 2023 to $54.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to risen viral infections, patient preference for combination treatments, emergence of drug resistance, advancements in virology and immunology, global healthcare initiatives.
The antiviral combination therapy market size is…
Aluminum Composite Panels Market on Upward Trajectory: Expected to Reach $8.83B …
The aluminum composite panels market size has grown strongly in recent years. It will grow from $6.13 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to architectural growth and modern construction trends, increasing urbanization and infrastructure development, durability and weather resistance, versatility in design and aesthetic appeal, cost-effectiveness and material efficiency.
The aluminum…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
